Genesee Capital Advisors LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

Genesee Capital Advisors LLC bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 36,749 shares of the company’s stock, valued at approximately $889,000.

Several other institutional investors and hedge funds have also made changes to their positions in HIMS. Raleigh Capital Management Inc. increased its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares in the last quarter. Quest Partners LLC raised its stake in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. CWM LLC lifted its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Hims & Hers Health by 115.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock valued at $110,000 after purchasing an additional 2,442 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, COO Melissa Baird sold 58,750 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $21.04, for a total value of $1,236,100.00. Following the transaction, the chief operating officer now owns 630,166 shares of the company’s stock, valued at $13,258,692.64. This represents a 8.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,256,067 shares of company stock worth $34,459,485 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Up 3.1 %

NYSE:HIMS opened at $31.46 on Wednesday. The company has a market cap of $6.87 billion, a PE ratio of 71.49 and a beta of 1.31. The business’s 50 day moving average is $28.57 and its two-hundred day moving average is $22.33. Hims & Hers Health, Inc. has a 52 week low of $8.51 and a 52 week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.04) EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. Canaccord Genuity Group increased their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Morgan Stanley began coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Finally, TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.